NYSE: PTN - Palatin Technologies, Inc.

Yield per half year: -83.74%
Dividend yield: 0%
Sector: Healthcare

Share chart Palatin Technologies, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Palatin Technologies, Inc.

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases.

more details
In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 1993-10-28
ISIN US6960775020
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://palatin.com
Цена ао 0.0914
Change price per day: 0% (0.1545)
Change price per week: +58.46% (0.0975)
Change price per month: -38.2% (0.25)
Change price per 3 month: -84.55% (1)
Change price per half year: -83.74% (0.95)
Change price per year: -92.28% (2)
Change price per 3 year: -58.24% (0.37)
Change price per 5 year: -63.27% (0.4206)
Change price per year to date: -86.08% (1.11)
All parameters

Underestimation

Title Value Grade
P/S 5.96 2
P/BV -239.91 0
P/E 0 0
EV/EBITDA -0.6135 0
Total: 4

Efficiency

Title Value Grade
ROA, % -207.35 0
ROE, % -263431.19 0
Total: 1.67

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0.0071

Debt

Title Value Grade
Debt/EBITDA -0.0203 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 3705.16 10
Yield Ebitda, % 23.01 4
Yield EPS, % -10.08 0
Total: 4
More

Institutions Volume Share, %
Armistice Capital, LLC 590000 3.66
Vanguard Group Inc 548622 3.4
LPL Financial LLC 146396 0.91
Blackrock Inc. 119518 0.74
Geode Capital Management, LLC 94148 0.58
State Street Corporation 30295 0.19
Susquehanna International Group, LLP 30062 0.19
Bridgeway Capital Management, Inc. 26124 0.16
Northern Trust Corporation 25097 0.16
Montis Financial, LLC 20964 0.13



Head Job title Payment Year of birth
Dr. Carl Spana Ph.D. Co-Founder, President, CEO & Director 979k 1962 (63 years)
Mr. Stephen T. Wills CPA, MST CFO, COO, Executive VP, Treasurer & Secretary 910.55k 1957 (68 years)
Burns McClellan Vice President of Investor Relations N/A
Mr. Stephen A. Slusher Esq. Chief Legal Officer N/A
Dr. Michael B. Raizman M.D. Chief Medical Officer N/A
Mr. James E. Hattersley Senior Vice President of Business Development N/A 1960 (65 years)
Mr. John Dodd Ph.D. Senior Vice President of Preclinical Development N/A
Mr. Robert Jordan Senior Vice President of Program Operations N/A

Address: United States, Cranbury. NJ, Cedar Brook Corporate Center - open in Google maps, open in Yandex maps
Website: https://palatin.com